RxDoctor Payments Data

Daniel Tveit, MD

Nephrology · Slidell, LANPI 1942207162

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.1% of the total across 401 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations.

$6,928in general payments, 2019–2025

Across 401 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$854
  • Vifor Pharma, Inc.$690
  • Akebia Therapeutics Inc$677
  • Otsuka America Pharmaceutical, Inc.$629
  • Mallinckrodt Hospital Products Inc.$489
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$6,66296%
  • Education$2674%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,928 in reported general payments places this provider in the 80th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$255,397
Medicare patients
464
Services billed
2,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$263,574
RayaldeeCalcifediol21$31,205
FarxigaDapagliflozin Propanediol24$24,475
Cinacalcet Hcl78$24,308
LokelmaSodium Zirconium Cyclosilicate19$19,998
JardianceEmpagliflozin18$18,516
VeltassaPatiromer Calcium Sorbitex11$7,323
ProsolParenteral Amino Acid 20% No.133$6,224
Calcitriol484$6,215
Sevelamer Carbonate18$4,167
Calcium Acetate22$1,970
Potassium Chloride87$1,876
Midodrine Hcl23$1,532
Tamsulosin Hcl109$1,304
Vitamin D2Ergocalciferol (Vitamin D2)89$1,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$629$263,57413 claims
AstraZenecaFarxiga, Lokelma$854$44,47443 claims
OPKO Pharmaceuticals, LLCRayaldee$417$31,20521 claims
Boehringer IngelheimJardiance$59$18,51618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 nephrology providers in Louisiana.

Other nephrology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →